TABLE 2.
Demographics and Mucosal Eosinophil Density of Nonresponder and Responders to Vedolizumab Therapy
| No response (n = 26) | Response (n = 39) | P | |
|---|---|---|---|
| Age at vedolizumab start (mean yrs ± SD) | 37.6 ± 18.9 | 38.4 ± 15.6 | 0.86 |
| Female (n, %) | 11 (42) | 28 (72) | 0.02 |
| BMI (mean kg/m2 ± SD) | 26.4 ± 6.2 | 30.4 ± 8.9 | 0.05 |
| Nonsmoker (n, %) | 20 (77) | 30 (77) | 0.77 |
| IBD type (n, %) | |||
| Crohn’s | 11 (42) | 20 (51) | 0.66 |
| UC | 15 (58) | 19 (49) | |
| Disease duration (mean yrs ± SD) | 9.9 ± 8.3 | 9.8 ± 8.6 | 0.97 |
| Hemoglobin (n = 64;mean mg/dl ± SD) | 12.4 ± 2.2 | 12.4 ± 1.7 | 0.98 |
| CRP (n = 50; mean mg/dl ± SD) | 10.0 ± 16.7 | 6.6 ± 7.6 | 0.52 |
| Concomitant immunomodulators with vedolizumab | |||
| Azathioprine, 6-mercaptopurine (n, %) | 4 (15) | 7 (18) | 0.82 |
| Methotrexate (n, %) | 6 (23) | 8 (21) | 0.78 |
| Prior Biologics (n, %) | |||
| Any prior anti-TNF (n, %) | 25 (96) | 22 (56) | 0.001 |
| More than one prior anti-TNF (n, %) | 16 (62) | 12 (31) | 0.01 |
| More than one prior class of biologic (n, %) | 1 (4) | 0 (0) | 0.22 |
| Any prior immunomodulator (n, %) | 19 (73) | 23 (29) | 0.24 |
| Any prior anti-TNF and immunomodulator (n, %) | 19 (73) | 16 (41) | 0.01 |
| Eosinophil counts | |||
| Peripheral eosinophil count (n = 40;mean eos x 109/L ± SD) | 260 ± 180 | 250 ± 210 | 0.80 |
| Mean mucosal eosinophil density (mean eos/mm2 ± SD) | 339.5 ± 155.7 | 235.2 ± 123.6 | 0.004 |
| Other histologic findings (n, %) | |||
| Eosinophil degranulation | 25 (96) | 35 (90) | 0.34 |
| Eosinophil microabscesses | 20 (77) | 27 (68) | 0.50 |
| Diffuse eosinophils on biopsy | 18 (69) | 27 (69) | 1.0 |
| Extensive epithelial damage | 13 (50) | 17 (45) | 0.63 |
| Severe architectural changes | 9 (36) | 16 (41) | 0.80 |
| Diffuse polymorphonuclear neutrophils on biopsy | 7 (27) | 5 (13) | 0.24 |
| Erosions/ulcers | 18 (72) | 25 (64) | 0.51 |
| Granulomas (CD) | 6 (23) | 8 (21) | 0.85 |
| ≥50% crypts involved (UC) | 6 (40) | 9 (45) | 0.71 |